<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141514</url>
  </required_header>
  <id_info>
    <org_study_id>2019/CHU/03</org_study_id>
    <nct_id>NCT04141514</nct_id>
  </id_info>
  <brief_title>Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy</brief_title>
  <acronym>CHEMO-FAST</acronym>
  <official_title>Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the effect of the practice of a short-term partial fasting&#xD;
      compared to a usual alimentation on nausea and vomiting within 5 days after the start of a&#xD;
      chemotherapy session on 2 successive chemotherapy courses (4 sessions of chemotherapy) in&#xD;
      patients starting treatment with highly emetogenic chemotherapy (ABVD or AVD protocol).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in fasting arm will practice partial fasting during 3 days (D-1, D1 (D day of&#xD;
      chemotherapy) and D2) following a food guide during 4 chemotherapy sessions. Patients in&#xD;
      usual alimentation arm will continue to take food as usual practice.&#xD;
&#xD;
      In each arm, patients will be interviewed at each chemotherapy sessions about nausea and&#xD;
      vomiting (number and intensity of nausea and vomiting, treatments taken). Denutrition,&#xD;
      quality of life improvement, compliance to partial fasting, treatment response will be&#xD;
      evaluate too.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>Day 1 (first day of the chemotherapy cycle),</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 2 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 3 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 4 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea and vomiting evaluation and quantification</measure>
    <time_frame>day 5 of the chemotherapy cycle</time_frame>
    <description>Anti-emetic tool from MASCC (Multinational Association of Supportive Care in Cancer)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nausea Post Chemotherapy</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual alimentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>therapeutic fasting</intervention_name>
    <description>fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient starting a treatment by chemotherapy ABVD or AVD&#xD;
&#xD;
          -  patient affiliated to a social security scheme&#xD;
&#xD;
          -  patient who gives his informed consent before any procedure related to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with diabetes&#xD;
&#xD;
          -  patient with recent gastric ulcer&#xD;
&#xD;
          -  patient with low BMI (less than 18,5 for patients under 70 or less than 21 for patient&#xD;
             over 70)&#xD;
&#xD;
          -  albuminemia &lt;35&#xD;
&#xD;
          -  patient wiht loss weight &gt; 10% in 6 months&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  chronic alcoholism&#xD;
&#xD;
          -  unable to understand the objectives and risks of the study&#xD;
&#xD;
          -  patient with psychiatric desorder, under guardianship or under judicial protection&#xD;
&#xD;
          -  patient who cannot read&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Elora MUSSARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de La Réunion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mélanie BEGORRE</last_name>
    <phone>+262 (0)262 90 78 85</phone>
    <email>melanie.begorre@chu-reunion.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de la Réunion</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97410</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ELORA MUSSARD</last_name>
      <phone>0262358759</phone>
      <email>elora.grondin@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

